Abstract:Background: Mesenchymal stromal cells (MSCs) have broad potential as a cell therapy including for the treatment of drug-resistant inflammatory conditions with abnormal T cell proliferation such as graft-versus-host disease (GVHD). Clinical success, however, has been complicated by the heterogeneity of culture-expanded MSCs as well as donor variability. Here, we devise culture conditions that promote expansion of MSCs with enhanced immunomodulatory functions both in vitro and in animal models of GVHD. Methods: Human bone marrow-derived MSCs were expanded at high-confluency (MSCHC) and low-confluency state (MSCLC). Their immunomodulatory properties were evaluated with in vitro co-culture assays based on suppression of activated T cell proliferation and secretion of pro-inflammatory cytokines from activated T cells. Metabolic state of these cells was determined, while RNA sequencing was performed to explore transcriptome of these MSCs. Ex vivo expanded MSCHC or MSCLC was injected into human peripheral blood mononuclear cells (PBMC)-induced GVHD mouse model to determine their in vivo therapeutic efficacy based on clinical grade scoring, human CD45+ blood count and histopathological examination. Results: As compared to MSCLC, MSCHC significantly reduced both the proliferation of anti-CD3/CD28-activated T cells and secretion of pro-inflammatory cytokines upon MSCHC co-culture across several donors even in the absence of cytokine priming. Mechanistically, metabolic analysis of MSCHC prior to co-culture with activated T cells showed increased glycolytic metabolism and lactate secretion compared to MSCLC, consistent with their ability to inhibit T cell proliferation. Transcriptome analysis further revealed differential expression of immunomodulatory genes including TRIM29, BPIFB4, MMP3 and SPP1 in MSCHC as well as enriched pathways including cytokine-cytokine receptor interactions, cell adhesion and PI3K-AKT signalling. Lastly, we demonstrate in a human PBMC-induced GVHD mouse model that delivery of MSCHC showed greater suppression of inflammation and improved outcomes compared to MSCLC and saline controls. Conclusion: Our study provides evidence that ex vivo expansion of MSCs at high confluency alters the metabolic and transcriptomic states of these cells. Importantly, this approach maximizes the production of MSCs with enhanced immunomodulatory functions without priming, thus providing a non-invasive and generalizable strategy for improving the use of MSCs for the treatment of inflammatory diseases.

In Situ Licensing of Mesenchymal Stem Cell Immunomodulatory Function Via BMP-2 Induced Developmental Process.

Immunomodulatory potential of cytokine-licensed human bone marrow-derived mesenchymal stromal cells correlates with potency marker expression profile

Harnessing the Properties of Biomaterial to Enhance the Immunomodulation of Mesenchymal Stem Cells

The Immunologic Properties of Undifferentiated and Osteogenic Differentiated Mouse Mesenchymal Stem Cells and Its Potential Application in Bone Regeneration.

Bone Marrow Mesenchymal Stem Cells Expanded Inside the Nichoid Micro-Scaffold: a Focus on Anti-Inflammatory Response

TNF ‐a/ IL‐1B cytokine licensing enhances immunomodulatory potential of allogeneic mesenchymal stromal cells

Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis

Expansion of human bone marrow-derived mesenchymal stromal cells with enhanced immunomodulatory properties

Molecular Targeting Regulation of Proliferation and Differentiation of the Bone Marrow-Derived Mesenchymal Stem Cells or Mesenchymal Stromal Cells

Enhanced Immunosuppression of T Cells by Sustained Presentation of Bioactive Interferon-γ Within Three-Dimensional Mesenchymal Stem Cell Constructs

Improving the immunomodulatory function of mesenchymal stem cells by defined chemical approach

Fabrication of Interleukin-4 Encapsulated Bioactive Microdroplets for Regulating Inflammation and Promoting Osteogenesis

Mesenchymal Stem Cells Attenuated PLGA-induced Inflammatory Responses by Inhibiting Host DC Maturation and Function.

Soluble molecules are key in maintaining the immunomodulatory activity of murine mesenchymal stromal cells.

Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair

Establishment of NF-κB sensing and interleukin-4 secreting mesenchymal stromal cells as an "on-demand" drug delivery system to modulate inflammation

An In Vitro Model to Test the Influence of Immune Cell Secretome on Mesenchymal Stromal Cell Osteogenic Differentiation

Regulation of the Stem Cell–Host Immune System Interplay Using Hydrogel Coencapsulation System with an Anti‐Inflammatory Drug

PDGF-BB and IL-4 co-overexpression is a potential strategy to enhance mesenchymal stem cell-based bone regeneration

[Immunocharacteristics of Bone Marrow Mesenchymal Stem Cell].

Immunomodulatory and Osteogenic Differentiation Effects of Mesenchymal Stem Cells by Adenovirus‐mediated Coexpression of CTLA4Ig and BMP2